With 1.61 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.48 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $2.68 whereas the lowest price it dropped to was $2.08. The 52-week range on SXTC shows that it touched its highest point at $11.92 and its lowest point at $0.97 during that stretch. Beta for the stock currently stands at 1.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SXTC was up-trending over the past week, with a rise of 138.24%, but this was down by -10.66% over a month. Three-month performance dropped to -33.82% while six-month performance fell -50.29%. The stock lost -71.61% in the past year, while it has lost -40.22% so far this year.
Float and Shares Shorts:
At present, 13.76 million SXTC shares are outstanding with a float of 13.73 million shares on hand for trading. On 2025-04-15, short shares totaled 51288.0, which was 37.0 higher than short shares on 1741910400. In addition to Mr. Feng Zhou as the firm’s Chairman of the Board & Co-CEO, Mr. Xiaodong Pan serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.0018000001 of SXTC’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
